Abstract
An AFF is a form of stress fracture induced by excessive physiologic repetitive stress over the bone remodeling capacity. Although glucocorticoid administration is a known risk factor for AFF, no case of AFF with glucocorticoid administration as the only risk factor has been previously reported. In this report, we aimed to highlight the risk of AFF associated with long-term administration of glucocorticoids, and the importance of surveillance and correction of risk factors in patients undergoing long-term glucocorticoid therapy. A 58-year-old male patient was diagnosed with subtrochanteric AFF. He had no medical history of any condition that might disrupt bone metabolism and no known risk factors for AFF, except for long-term administration of glucocorticoid. After fixation of the fracture, the glucocorticoid was replaced with an alternative medication. Although AFF is notorious for delayed union or nonunion, complete union of the fracture was obtained at 14 months postoperatively. This case brought to our attention the possibility that glucocorticoids alone may be responsible for inducing AFF and highlighted the importance of regular assessments in case of necessity of glucocorticoid administration. Additionally, correction of risk factors might expedite the union of AFF.
Similar content being viewed by others
Data availability
None.
References
Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23
Tantavisut S, Tanavalee A, Thanakit V, Ngarmukos S, Wilairatana V, Wangroongsub Y (2014) Spontaneous acetabular periprosthetic fracture in a patient continuously having zoledronic acid. Clin Orthop Surg 6:358–360
Oh BH, Heo YM, Yi JW, Kim TG, Lee JS (2018) Atypical fracture of the proximal shaft of the ulna associated with prolonged bisphosphonate therapy. Clin Orthop Surg 10:389–392
Starr J, Tay YKD, Shane E (2018) Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures. Curr Osteoporos Rep 16:519–529
Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000
Head K, Chong LY, Hopkins C, Philpott C, Burton MJ, Schilder AG (2016) Short-course oral steroids alone for chronic rhinosinusitis. Cochrane Database Syst Rev 4:CD011991
Campbell RG (2018) Risks and management of long-term corticosteroid use in chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 26:1–7
Compston J (2018) Glucocorticoid-induced osteoporosis: an update. Endocrine 61:7–16
Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N (2019) Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev 40:333–368
Nishino T, Hyodo K, Matsumoto Y, Yanagisawa Y, Yoshizawa T, Yamazaki M (2020) Surgical results of atypical femoral fractures in long-term bisphosphonate and glucocorticoid users - relationship between fracture reduction and bone union. J Orthop 19:143–149
Wilkerson J, Fernando ND (2020) Classifications in brief: the Dorr classification of femoral bone. Clin Orthop Relat Res 478:1939–1944
Lim SJ, So SY, Yoon YC, Cho WT, Oh JK (2015) A forward-striking technique for reducing fracture gaps during intramedullary nailing: a technical note with clinical results. Injury 46:2507–2511
Kanis JA, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3–44
Schilcher J, Koeppen V, Aspenberg P, Michaelsson K (2015) Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop 86:100–107
Nishimura J, Ikuyama S (2000) Glucocorticoid-induced osteoporosis: pathogenesis and management. J Bone Miner Metab 18:350–352
Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, Novack D (2009) Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 85:37–44
Schilcher J, Michaelsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737
Lo JC, Huang SY, Lee GA, Khandelwal S, Provus J, Ettinger B, Gonzalez JR, Hui RL, Grimsrud CD (2012) Clinical correlates of atypical femoral fracture. Bone 51:181–184
Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, Dell RM, Adams AL (2020) Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 383:743–753
Paragliola RM, Papi G, Pontecorvi A, Corsello SM (2017) Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis. Int J Mol Sci 18
Code availability
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval and consent to participate
The study design and protocol were approved by the institutional review board of the Ajou University Medical center (IRB No.: AJIRB-MED-EXP-20-414). The patient was informed that information involving this case would be presented for publication and gave informed consent.
Consent for publication
All authors approved.
Conflicts of interest
None.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kim, JT., Cha, YH., Jeong, S. et al. Subtrochanteric atypical femoral fracture induced solely by glucocorticoid without bisphosphonate treatment: a case report. Osteoporos Int 32, 2115–2118 (2021). https://doi.org/10.1007/s00198-021-05971-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-021-05971-x